ICLN vs XBI
iShares Global Clean Energy ETF vs SPDR S&P Biotech ETF
- • XBI has the lower expense ratio at 0.35% vs 0.39% for ICLN.
- • ICLN pays a higher dividend yield (1.30%).
Side-by-side metrics
| Metric | ICLN | XBI |
|---|---|---|
Expense ratio Annual fee. Lower is better. | 0.39% | 0.35% |
Dividend yield Trailing 12-month yield. | 1.30% | 0.34% |
AUM Assets under management — bigger funds are typically more liquid. | $2.50B | $8.30B |
YTD return | 29.76% | 12.92% |
1-year return | — | — |
3-year return Annualized. | — | — |
5-year return Annualized. | — | — |
10-year return Annualized. | — | — |
Beta (3Y) Volatility relative to the market. Closer to 1 = market-like. | 1.26 | 1.09 |
P/E ratio | 22.19 | — |
Last price | $20.71 | $133.66 |
Inception | — | — |
Issuer | iShares | State Street |
ICLN top holdings
| BE | Bloom Energy Corp Class A | 13.73% |
| NXT | Nextpower Inc Class A | 7.28% |
| FSLR | First Solar Inc | 7.15% |
| 600900.SS | China Yangtze Power Co Ltd Class A | 5.89% |
| VWS.CO | Vestas Wind Systems AS | 3.35% |
| PLUG | Plug Power Inc | 3.28% |
| ENPH | Enphase Energy Inc | 3.24% |
| EQTL3.SA | Equatorial SA | 2.87% |
| SUZLON.BO | Suzlon Energy Ltd | 2.36% |
| EDP.LS | EDP-Energias De Portugal SA | 2.33% |
XBI top holdings
| APLS | Apellis Pharmaceuticals Inc | 1.87% |
| RVMD | Revolution Medicines Inc Ordinary Shares | 1.65% |
| TVTX | Travere Therapeutics Inc Ordinary Shares | 1.62% |
| ARWR | Arrowhead Pharmaceuticals Inc | 1.44% |
| TWST | Twist Bioscience Corp | 1.42% |
| SMMT | Summit Therapeutics Inc Ordinary Shares | 1.40% |
| ALKS | Alkermes PLC | 1.38% |
| TGTX | TG Therapeutics Inc | 1.37% |
| MDGL | Madrigal Pharmaceuticals Inc | 1.36% |
| BEAM | Beam Therapeutics Inc | 1.32% |
About ICLN
ICLN (iShares Global Clean Energy ETF) is Global clean energy and renewable power companies. Managed by iShares, the fund carries $2.5B in assets under management, an expense ratio of 0.39%, a dividend yield of 1.30%. Its largest holding is Bloom Energy Corp Class A (BE), which represents 13.7% of the portfolio. Basic Materials is the fund's largest sector exposure at 1.7%.
About XBI
XBI (SPDR S&P Biotech ETF) is Equal-weight biotech stocks in the S&P Biotech Index. Managed by State Street, the fund carries $8.3B in assets under management, an expense ratio of 0.35%, a dividend yield of 0.34%. Its largest holding is Apellis Pharmaceuticals Inc (APLS), which represents 1.9% of the portfolio. Financial Services is the fund's largest sector exposure at 0.2%.